vaccin
recogn
worldwid
one
import
tool
combat
infecti
diseas
despit
tremend
valu
confer
current
avail
vaccin
toward
public
health
implement
addit
vaccin
platform
also
key
import
fact
current
avail
vaccin
possess
shortcom
ineffici
trigger
cellmedi
immun
respons
lack
protect
mucos
immun
regard
recent
work
focus
vaccin
deliveri
system
altern
inject
vaccin
increas
antigen
stabil
improv
overal
immunogen
particular
novel
strategi
base
edibl
intraderm
vaccin
formul
demonstr
trigger
system
mucos
immun
respons
novel
vaccin
deliveri
system
offer
sever
advantag
inject
prepar
includ
selfadministr
reduc
cost
stabil
elimin
cold
chain
review
latest
find
accomplish
regard
edibl
intraderm
vaccin
describ
context
system
use
immunogen
express
molecular
featur
capac
induc
protect
system
mucos
respons
one
ten
greatest
public
health
achiev
last
centuri
prevent
vaccin
vaccin
success
reduc
spread
diseas
mitig
mortal
associ
infecti
agent
diphtheria
tetanu
polio
measl
mump
rubella
hepat
b
spite
mani
success
achiev
vaccin
novel
technolog
administr
rout
remain
one
main
focus
vaccinolog
field
although
mani
licens
vaccin
administ
inject
certain
case
administr
rout
suffer
limit
particular
inject
vaccin
requir
train
personnel
administr
vaccin
may
requir
multipl
dose
inclus
adjuv
moreov
inject
vaccin
may
requir
special
storag
transport
condit
immunolog
point
view
inject
vaccin
capabl
elicit
robust
system
humor
respons
confer
weaker
cellmedi
immun
mucos
protect
importantli
cell
effector
activ
mucos
immun
contribut
prevent
control
infect
pathogen
target
mucosa
improv
limit
altern
vaccin
deliveri
method
coupl
novel
formul
product
system
recent
propos
numer
studi
focus
vaccin
deliv
mucos
interfac
intraderm
demonstr
rapid
wide
biodistribut
antigen
capac
induc
protect
mucos
mainli
mediat
secretori
iga
siga
system
cellular
humor
respons
review
discuss
current
advanc
advantag
edibl
system
base
plant
alga
yeast
insect
cell
lactic
acid
bacteria
intraderm
immun
rout
mucos
deliveri
immun
respons
efficaci
mucos
administr
rout
larg
base
fact
mucou
membran
constitut
largest
immunolog
organ
bodi
moreov
interfac
endow
wellorgan
lymphat
structur
term
mucosaassoci
lymphoid
tissu
malt
contain
innat
adapt
b
cell
arm
immun
system
furthermor
antigenspecif
siga
play
pivot
role
protect
mucos
surfac
microb
adhes
toxin
activ
thu
develop
novel
vaccin
deliveri
platform
implement
elicit
pathogenor
toxinspecif
siga
well
system
igg
pivot
improv
vaccin
effect
date
wellstudi
vaccin
deliveri
platform
capabl
elicit
mucos
system
immun
edibl
intraderm
vaccin
formul
figur
oral
vaccin
stimul
gener
immun
gutassoci
lymphoid
tissu
galt
includ
lymph
node
peyer
patch
lymphocyt
major
compon
b
cell
cell
isol
lymphoid
follicl
gastrointestin
tract
git
effect
immun
use
oral
vaccin
achiev
suffici
quantiti
antigen
transport
across
mucos
barrier
cell
peyer
patch
subsequ
present
cell
antigenpres
cell
apc
briefli
profession
apc
display
peptid
fragment
antigen
context
major
histocompat
complex
mhc
surfac
lead
activ
cell
subsequ
activ
cell
support
germin
center
develop
includ
b
cell
affin
matur
class
switch
iga
provid
ligand
interact
cytokin
secret
moreov
express
specif
chemokin
home
receptor
eg
antigenexperienc
b
cell
migrat
distant
effector
region
differenti
plasma
cell
capabl
secret
dimer
polymer
figur
altern
method
vaccin
deliveri
develop
ration
design
vaccin
start
identif
gene
encod
protect
antigen
protein
subsequ
antigen
incorpor
differ
edibl
system
plant
alga
insect
yeast
use
intraderm
formul
induc
mucos
protect
respons
follow
administr
edibl
vaccin
subsequ
passag
antigen
cell
compart
deliv
dendrit
cell
individu
immun
system
trigger
respons
lead
also
specif
iga
product
secret
similarli
patch
coat
microproject
biodegrad
needl
activ
langerhan
cell
dermal
dendrit
cell
skin
dermi
cell
captur
present
antigen
b
lymphocyt
trigger
mucos
system
immun
iga
molecul
transport
intestin
lumen
siga
context
edibl
vaccin
aim
elicit
pathogenspecif
respons
necessari
overcom
mucos
toler
briefli
mucos
toler
achiev
certain
foreign
antigen
contain
food
serv
prevent
unnecessari
potenti
detriment
immun
respons
gut
mucosa
due
phenomenon
erron
mucos
vaccin
formul
could
induc
reg
base
tolerogen
respons
instead
protect
immun
potenti
shortcom
circumv
use
sever
strategi
includ
incorpor
appropri
adjuv
vaccin
formul
use
suffici
high
dose
antigen
promot
induct
effector
rather
regulatori
cell
moreov
context
ediblebas
vaccin
immun
also
import
consid
characterist
git
sever
factor
includ
proteolyt
enzym
acid
ph
bile
salt
limit
permeabl
may
hinder
induct
protect
immun
respons
end
conjug
vaccin
antigen
specif
ligand
enhanc
uptak
cell
repres
focu
ongo
studi
aim
improv
immunogen
moreov
antigen
bioencapsul
avoid
degrad
conform
alter
follow
section
review
variou
strategi
underli
develop
edibl
vaccin
particular
focus
plant
alga
insect
cell
whole
yeast
lactic
acid
bacteriabas
vaccin
describ
advantag
limit
individu
system
plant
extens
use
develop
novel
biopharmaceuticalproduc
platform
recent
year
promot
proper
fold
exogen
protein
econom
sustain
also
known
context
molecular
farm
biomolecul
commerci
valu
produc
genet
engin
plant
sever
ongo
clinic
trial
use
purifi
antigen
transient
produc
tobacco
plant
nicotiana
benthamiana
inject
vaccin
formul
exampl
medicago
recent
complet
phase
ii
clinic
trial
use
plantderiv
viruslik
particl
vlp
quadrival
influenza
vaccin
announc
phase
iii
clinic
studi
last
year
clinicaltrialsgov
identifi
owe
fact
plant
edibl
notion
could
serv
deliveri
vehicl
well
biofactori
led
use
oral
vaccin
earli
recent
year
addit
studi
sought
overcom
limit
convent
vaccin
develop
edibl
formul
sinc
incept
idea
evid
use
plant
produc
vaccin
would
sever
advantag
first
plant
vaccin
would
like
low
product
cost
could
easili
scaledup
demonstr
biopharmaceut
industri
molecular
farm
gain
visibl
thank
success
zmapp
experiment
drug
ebola
viru
produc
nicotiana
plant
howev
unlik
biomolecul
product
edibl
vaccin
formul
need
process
purif
step
administr
serv
lower
productionassoci
cost
inde
anoth
advantag
strategi
plant
cell
would
provid
antigen
protect
due
rigid
cell
wall
also
known
bioencapsul
effect
could
increas
bioavail
antigen
molecul
galt
preserv
structur
integr
vaccin
compon
stomach
elicit
mucos
system
immun
respons
addit
strategi
antigen
protect
achiev
target
biomolecul
express
insid
chloroplast
storag
organel
protein
bodi
seed
technolog
also
offer
advantag
term
storag
cold
chainfre
deliveri
due
high
stabil
express
antigen
bioencapsul
within
plant
seed
tissu
moreov
plant
materi
store
elev
temperatur
longer
period
grown
need
make
strategi
even
attract
develop
countri
final
plantbas
oral
vaccin
character
improv
safeti
rel
tradit
recombin
vaccin
platform
especi
sinc
contamin
mammalianspecif
pathogen
elimin
inde
studi
use
lyophil
leav
shown
advantag
fresh
materi
longterm
stabil
higher
antigen
content
lower
microbi
contamin
exampl
freezedri
ctb
cholera
toxin
b
subunit
leav
shown
stabl
month
room
temperatur
lettuc
express
solubl
antigen
pa
protect
antigen
bacillu
anthraci
success
store
month
room
temperatur
without
show
antigen
degrad
antigen
content
lyophil
leaf
materi
also
higher
fresh
leav
addit
benefit
lyophil
abil
remov
microbi
contamin
lyophil
lettuc
detect
microb
fresh
leav
contain
approxim
cfug
microb
plate
variou
grow
media
date
vaccin
antigen
transform
mani
edibl
speci
includ
lettuc
tomato
potato
papaya
carrot
quinoa
tobacco
proper
fold
enhanc
express
also
test
anim
model
prove
immunogen
antigen
produc
system
obtain
high
quantiti
protein
interest
nuclear
chloroplast
genom
success
engin
howev
latter
option
prefer
owe
advantag
includ
high
level
transgen
express
total
solubl
protein
tsp
bioencapsul
effect
regulatori
concern
sinc
transgen
contain
assur
fact
plastid
spread
via
pollen
plant
moreov
incorpor
vaccin
antigen
chloroplast
genom
would
also
enabl
express
multipl
gene
singl
operon
would
attract
multival
vaccin
develop
likewis
approach
may
enabl
product
vaccin
confer
protect
multipl
infecti
agent
would
serv
reduc
cost
associ
vaccin
product
administr
unfortun
disadvantag
undermin
applic
first
plastid
suitabl
product
antigen
requir
glycosyl
proper
fold
antigen
protect
immun
respons
requir
glycan
recognit
howev
nuclear
transform
repres
valid
option
secondli
antigen
express
either
transient
stabl
plant
second
prefer
order
obtain
stabl
genet
resourc
fact
transgen
seed
repres
constant
resourc
grow
transgen
plant
extract
protein
howev
stabl
transform
timeconsum
moreov
express
stabl
transform
crop
plant
suffer
low
yield
typic
less
tsp
hand
transient
express
technolog
use
either
agrobacterium
viral
vector
robust
quick
easi
manipul
howev
express
typic
unstabl
anoth
import
challeng
plantbas
oral
vaccin
lack
proper
dose
strategi
low
dose
may
abl
induc
suffici
immun
respons
high
dose
previous
describ
may
lead
immun
toler
end
freezedri
method
implement
stabil
plant
biomass
concentr
antigen
achiev
accur
dosag
quantifi
antigen
term
dri
biomass
weight
mention
date
plantbas
vaccin
hepat
b
viru
hbv
rabi
viru
norwalk
viru
enterotoxigen
e
coli
vibrio
cholera
phase
clinic
trial
tabl
mani
other
still
preclin
develop
includ
vaccin
target
varieti
pathogen
avian
influenza
virus
hpai
helicobact
pylori
coronavirus
algaebas
vaccin
green
microalga
chlamydomona
reinhardtii
repres
anoth
viabl
option
vaccin
product
howev
disadvantag
plantderiv
vaccin
low
express
level
improp
glycosyl
antigen
protein
describ
thu
far
chloroplast
transform
possibl
singl
organel
present
even
occupi
half
cell
volum
stabl
transform
line
green
alga
easi
obtain
lead
increas
yield
express
antigen
fact
unicellular
green
alga
posit
characterist
plant
system
plu
uniqu
advantag
terrestri
plant
biomass
accumul
extrem
fast
use
entireti
growth
neither
season
constraint
reli
soil
fertil
crosscontamin
nearbi
crop
occur
alga
cultur
enclos
bioreactor
furthermor
regard
regulatori
aspect
green
alga
c
reinhardtii
gener
recogn
safe
gra
fda
final
alga
easili
lyophil
dri
store
room
temperatur
month
without
lose
antigen
efficaci
fact
alga
cell
wall
assur
bioencapsul
effect
proven
prevent
antigen
degrad
enzym
git
collect
characterist
indic
alga
would
ideal
host
vaccin
transport
without
cold
chain
suppli
thu
alreadi
describ
plantderiv
edibl
vaccin
low
cost
simpler
logist
term
manufactur
storag
deliveri
administr
algaebas
technolog
make
ideal
system
context
resourcelimit
set
compar
convent
vaccin
formul
algaebas
vaccin
current
clinic
trial
howev
preclin
formul
human
papillomaviru
hpv
hbv
footandmouth
diseas
viru
fmdv
develop
overcom
technic
problem
low
express
level
nuclear
genom
lack
glycosyl
follow
chloroplast
express
insect
cellbas
vaccin
insect
cell
system
wide
adopt
capac
produc
high
level
protein
perform
cotransl
posttransl
modif
includ
glycosyl
phosphoryl
protein
process
express
platform
allow
gener
stabl
transform
cell
line
transient
express
driven
recombin
baculoviru
infect
baculovirusinsect
cell
express
system
refer
bev
one
wellknown
use
system
largescal
product
complex
protein
recent
develop
subunit
vaccin
date
three
commerci
avail
vaccin
produc
insect
cell
differ
indic
cervarix
gsk
cervic
cancer
flublok
protein
scienc
own
sanofi
pasteur
influenza
proveng
dendreon
prostat
cancer
importantli
baculoviru
express
system
limit
cultur
cell
insect
larva
pupa
use
protein
product
context
edibl
vaccin
use
insect
larva
pupa
silkworm
bombyx
mori
larva
pupa
commerci
use
product
recombin
protein
also
feasibl
deliveri
system
vaccin
mention
baculovirussilkworm
express
system
abl
perform
cotransl
posttransl
modif
also
abl
produc
larg
amount
multipl
protein
moreov
sinc
baculoviru
unabl
replic
vertebr
anim
consid
gra
furthermor
presenc
proteas
inhibitor
biocapsulelik
fat
silkworm
may
protect
recombin
protein
enzymat
digest
git
sever
vaccin
prototyp
current
evalu
strong
system
immun
protect
respons
support
use
silkworm
mucos
vaccin
vector
shown
exampl
high
immunogen
mice
ureas
b
subunit
helicobact
pylori
produc
silkworm
data
collect
far
support
possibl
use
baculovirussilkworm
vaccin
promis
edibl
vaccin
platform
approv
food
ingest
asian
countri
wholecel
yeastbas
vaccin
industri
usag
yeast
cell
product
heterolog
protein
well
describ
addit
capabl
system
perform
posttransl
modif
gra
statu
cellular
wall
could
protect
antigen
across
git
make
engin
yeast
attract
vaccin
deliveri
system
addit
major
drawback
system
hyperglycosyl
recombin
protein
alreadi
address
gener
defect
nglycosyl
strain
yeast
wholecel
yeastbas
vaccin
studi
abil
elicit
immun
respons
remark
preclin
studi
base
oral
administr
saccharomyc
cerevisia
develop
differ
infecti
agent
hpv
actinobacillu
pleuropneumonia
show
deliveri
system
abl
induc
protect
mucos
system
immun
respons
moreov
increas
immunogen
deliveri
system
could
explain
adjuv
activ
yeast
cell
wall
demonstr
immunomodulatori
adjuv
effect
bind
innat
pathogen
receptor
macrophag
dc
neutrophil
current
two
clinic
trial
develop
hbv
treatment
hepat
c
viru
hcv
treatment
tabl
regard
clinic
trial
despit
posit
result
obtain
phase
second
phase
conduct
viral
suppress
noncirrhot
patient
chronic
hbv
infect
show
clinic
benefit
howev
safeti
efficaci
studi
conduct
anoth
group
patient
particular
patient
chronic
hbv
regard
clinic
trial
phase
ii
report
promis
result
particular
trial
use
also
combin
pegifnribavirin
howev
data
efficaci
publish
yet
lactic
acid
bacteria
lab
gramposit
nonsporul
nonpathogen
bacteria
use
decad
product
preserv
food
well
therapeut
heterolog
gene
express
like
product
differ
antihuman
immunodefici
viru
antihiv
antibodi
lactobacillu
jensenii
product
function
express
antilisteri
bacteriocin
enta
l
casei
given
abil
lab
elicit
specif
immun
respons
recombin
foreign
antigen
bacteria
consid
potenti
candid
mucos
vaccin
vector
deliveri
system
confer
protect
antigen
degrad
thank
uptak
git
level
activ
innat
adapt
immun
respons
mani
lab
particular
lactobacillu
spp
bacillu
subtili
use
preclin
studi
differ
infecti
diseas
differ
result
obtain
studi
elicit
immun
respons
observ
exampl
product
high
level
specif
iga
system
igg
immun
bacillu
spore
express
toxin
peptid
repeat
report
anoth
paper
l
lacti
express
hev
antigen
vaccin
test
specif
cellmedi
immun
respons
reveal
well
product
specif
mucos
iga
serum
igg
anoth
studi
report
immun
respons
elicit
immun
csenolaseexpress
bacillu
subtili
anoth
exampl
oral
administr
b
subtili
spore
express
ureas
b
helicobact
pylori
provid
protect
helicobact
infect
import
featur
lab
natur
adjuvant
immunomodulatori
effect
although
molecular
mechan
capabl
complet
understood
moreov
studi
report
effect
dendrit
cell
matur
induct
cytokin
secret
despit
promis
characterist
recombin
lab
mucos
vaccin
vector
given
encourag
result
murin
studi
aspect
need
taken
consider
name
fact
vaccin
strain
consid
avirul
even
could
list
gra
due
potenti
transfer
antibiot
select
marker
among
microb
furthermor
factor
import
develop
labbas
vaccin
exampl
necess
suitabl
deliveri
system
sinc
differ
administr
rout
produc
differ
immun
effect
addit
role
specif
adjuv
correct
local
intracellularli
bacteri
surfac
express
antigen
need
consider
overal
addit
studi
clinic
trial
need
develop
effici
vaccin
base
lab
differ
carrier
system
base
nonrecombin
lactococcu
lacti
bacteria
recent
develop
system
call
gramposit
enhanc
matrix
gem
compos
rigid
peptidoglycan
pgn
cell
wall
bacterium
result
nonliv
particl
preserv
shape
size
origin
bacterium
gem
use
two
differ
way
mix
vaccin
antigen
adjuv
antigen
protein
carrier
antigen
bound
surfac
gem
regard
use
gem
adjuv
natur
gem
safer
adjuv
compar
other
moreov
retain
inflammatori
properti
live
bacteria
enhanc
specif
mucos
system
immun
respons
influenza
subunit
vaccin
therefor
use
gem
examin
studi
investig
immun
respons
elicit
intranas
deliveri
influenza
subunit
vaccin
coadministr
gem
flugem
detail
influenzaspecif
memori
b
cell
respons
presenc
longliv
antibodysecret
plasma
cell
report
addit
immun
respons
abl
confer
protect
influenza
infect
import
result
obtain
murin
studi
led
phase
clinic
trial
confirm
posit
preclin
data
system
hemagglutin
inhibit
hai
titer
local
siga
respons
report
studi
assess
immun
respons
confer
protect
influenza
viru
gem
also
use
antigen
protein
carrier
particular
antigen
bound
gem
presenc
pgnbind
tag
protan
antigen
sever
work
use
vaccin
strategi
data
support
potenti
gem
safe
vaccin
deliveri
vehicl
abil
elicit
system
antibodi
moreov
gem
also
abl
present
sever
antigen
time
could
help
prepar
multival
vaccin
furthermor
deliveri
adjuv
gem
antigen
togeth
correl
enhanc
vaccin
immunogen
lastli
oppos
vaccin
base
lab
absenc
recombin
dna
avoid
dissemin
environ
howev
inabl
gem
colon
compart
allow
reduct
number
vaccin
dose
promis
premis
allow
develop
vaccin
respiratori
syncyti
viru
rsv
particular
intranas
formul
base
trimer
rsv
fusion
protein
coupl
gem
name
syngem
develop
also
case
posit
result
studi
mice
rat
obtain
flugem
vaccin
syngem
result
induct
robust
system
mucos
immun
respons
well
balanc
cytokin
profil
data
support
studi
vaccin
phase
clinic
trial
current
ongo
conclus
gem
repres
interest
vaccin
strategi
either
adjuv
antigen
protein
carrier
case
vaccin
base
lab
studi
need
immun
respons
anoth
vaccin
deliveri
rout
capabl
trigger
system
mucos
immun
intraderm
rout
antigen
deliv
skin
use
recent
develop
selfadministr
devic
particular
applic
microneedl
technolog
overcom
skin
permeat
barrier
impos
stratum
corneum
facilit
antigen
deliveri
efficaci
new
microneedlebas
immun
approach
due
presenc
sever
type
immun
cell
dc
lymphocyt
nk
cell
macrophag
mast
cell
epithelium
fact
cell
respons
trigger
inflamm
cascad
skin
langerhan
cell
compris
epitheli
cell
langerhan
cell
specif
dc
subset
migrat
lymph
node
follow
antigen
captur
aid
initi
adapt
immun
respons
cell
also
effici
stimul
pathogenassoci
molecular
pattern
pamp
use
array
germlineencod
pattern
recognit
receptor
prr
includ
tolllik
receptor
tlr
langerin
importantli
skin
resid
mast
cell
also
key
driver
innat
immun
respons
skin
releas
granul
contain
inflammatori
mediat
intraderm
vaccin
use
convent
syring
intramuscular
subcutan
vaccin
larg
volum
vaccin
solut
inject
ml
thu
choic
muscl
hypodermi
vaccin
target
mainli
base
conveni
intraderm
immun
vaccin
deliveri
upcom
strategi
show
signific
advantag
convent
vaccin
rout
particular
last
year
intraderm
vaccin
gain
momentum
altern
effect
vaccin
deliveri
rout
scientif
commerci
point
view
tabl
intraderm
vaccin
design
deliveri
antigen
directli
dermi
syring
needl
microneedl
pressur
injector
standard
intraderm
immun
techniqu
invent
french
physician
charl
mantoux
develop
tuberculin
test
techniqu
allow
inject
vaccin
solut
howev
mantoux
techniqu
requir
skill
medic
personnel
perform
recent
advanc
led
develop
techniqu
instrument
overcom
difficulti
associ
intraderm
administr
fact
differ
devic
develop
year
intraderm
vaccin
among
solid
microneedl
particl
injector
selfadministr
patch
coat
microproject
biodegrad
needl
describ
previous
mention
intraderm
vaccin
induc
mucos
system
immun
immunolog
capabl
coupl
eas
access
make
intraderm
rout
attract
vaccin
deliveri
target
intraderm
vaccin
demonstr
safe
fact
novel
devic
involv
use
needl
smaller
size
usual
mm
make
possibl
bypass
corneou
layer
epidermi
creat
transient
micropor
cutan
tissu
even
studi
shown
intraderm
vaccin
associ
higher
incid
local
reactogen
includ
primarili
mild
pain
swell
red
system
side
effect
report
fact
intraderm
rout
limit
transfer
vaccin
compon
blood
circul
risk
septic
shock
possibl
toxic
due
hepat
firstpass
effect
typic
present
local
effect
resolv
quickli
report
studi
compar
safeti
immunogen
larg
number
intraderm
versu
intramuscular
influenza
vaccin
anoth
import
aspect
possibl
improv
immunogen
variou
vaccin
immunocompromis
host
well
pregnanc
via
intraderm
rout
exampl
report
hbv
vaccin
fail
yield
seroconvers
recipi
howev
signific
improv
observ
follow
intraderm
vaccin
addit
demonstr
patient
dialysi
hivposit
subject
intraderm
rout
immunogen
standard
intramuscular
rout
commerci
point
view
intraderm
vaccin
primarili
explor
abil
elicit
equival
antibodi
respons
lower
dose
phenomenon
typic
describ
dose
spare
regard
advantag
low
dose
evid
highsurg
situat
pandem
season
influenza
wave
larg
popul
increas
risk
larg
amount
new
antigen
prepar
quickli
requir
year
dose
spare
also
import
largescal
set
reduc
productionassoci
cost
especi
develop
countri
price
vaccin
limit
use
coverag
regard
us
food
drug
administr
fda
approv
trival
inactiv
intraderm
influenza
vaccin
use
adult
year
age
use
season
quadrival
formul
subsequ
approv
howev
similar
intramuscular
vaccin
formul
approv
intraderm
vaccin
liquid
thu
still
depend
cold
chain
administ
syring
reason
novel
dri
solid
microneedl
devic
elicit
compar
immunogen
intramuscularadminist
vaccin
repres
innov
approach
facilit
selfadministr
allow
vaccin
storag
room
temperatur
infecti
diseas
repres
global
concern
effect
strategi
reduc
vaccin
unfortun
everi
diseas
current
prevent
vaccin
howev
mani
strategi
develop
infecti
agent
gener
neutral
antibodi
antibiot
antivir
drug
innov
approach
current
develop
mani
vaccin
develop
approv
variou
pathogen
countless
studi
conduct
improv
efficaci
test
new
adjuv
perform
ration
identif
antigen
formul
pathogen
contamin
promis
result
also
achiev
chang
deliveri
strategi
fact
approv
vaccin
administr
inject
intrins
limit
like
concern
immunolog
aspect
inject
vaccin
abl
elicit
strong
humor
immun
weak
cellular
respons
addit
type
administr
strongli
associ
system
immun
lack
mucos
respons
help
block
earli
stage
infect
sinc
pathogen
infect
mucos
membran
reason
new
vaccin
strategi
propos
particular
edibl
vaccin
trigger
galt
intraderm
approach
involv
langerhan
cell
abl
elicit
mucos
system
immun
respons
increas
knowledg
approach
led
progress
mani
preclin
studi
sever
promis
clinic
trial
tabl
moreov
vaccin
strategi
consid
safe
costeffect
extens
antigen
process
need
easi
administr
tabl
fact
due
opportun
selfadministr
eas
distribut
compar
injectionbas
approach
two
vaccin
system
could
improv
overal
coverag
remain
number
obstacl
drawback
associ
antigen
deliveri
platform
still
need
address
tabl
present
fdaapprov
compound
edibl
vaccin
new
emerg
technolog
like
nanoparticl
np
could
help
control
antigen
bioavail
avoid
mucos
toler
np
particl
mean
size
nm
nm
use
carrier
andor
adjuv
vaccin
prepar
moreov
np
target
specif
cell
popul
exampl
np
coat
antibodi
recogn
surfac
protein
dendrit
cell
approach
enabl
accur
measur
quantiti
antigen
requir
elicit
immun
respons
final
effici
immun
demonstr
use
npbase
approach
combin
intraderm
vaccin
deliveri
oral
deliveri
need
investig
test
vitro
conclus
novel
approach
elicit
stronger
mucos
respons
show
promis
result
preclin
clinic
studi
studi
need
implement
improv
deliveri
system
howev
mucos
deliveri
becom
prefer
mode
vaccin
